Patents by Inventor Denise O'Hara

Denise O'Hara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated cell comprising a nucleic acid encoding antibody inhibitors of gdf-8 and uses thereof
    Patent number: 9505831
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 29, 2016
    Assignee: Wyeth LLC
    Inventors: Jane Aghajanian, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
  • Antibody Inhibitors of GDF-8 and Uses Thereof
    Publication number: 20150024484
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Application
    Filed: April 18, 2014
    Publication date: January 22, 2015
    Applicant: Wyeth LLC
    Inventors: Jane Aghajanian, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
  • Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity
    Patent number: 8710202
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: April 29, 2014
    Assignee: Wyeth LLC
    Inventors: Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein, William J. Dunham
  • Antibody Inhibitors of GDF-8 and Uses Thereof
    Publication number: 20120107928
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 3, 2012
    Applicant: Wyeth LLC
    Inventors: Jane Aghajanian, William J. Dunham, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
  • Method of increasing trabecular bone density in a patient in need thereof by an antibody against GDF-8
    Patent number: 8092798
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: January 10, 2012
    Assignee: Wyeth LLC
    Inventors: Jane Aghajanian, William J. Dunham, legal representative, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
  • ANTIBODY INHIBITORS OF GDF-8 AND USES THEREOF
    Publication number: 20110020330
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Application
    Filed: May 24, 2010
    Publication date: January 27, 2011
    Applicant: Wyeth
    Inventors: Jane Aghajanian, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein, William J. Dunham
  • Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8
    Patent number: 7731961
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: June 8, 2010
    Assignee: Wyeth
    Inventors: Jane Aghajanian, William J. Dunham, legal representative, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
  • Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2
    Patent number: 7666421
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: February 23, 2010
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
    Patent number: 7531175
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: May 12, 2009
    Assignee: Genetics Institute LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Antibody inhibitors of GDF-8 and uses thereof
    Patent number: 7320789
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: January 22, 2008
    Assignee: Wyeth
    Inventors: William J. Dunham, legal representative, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Jane Aghajanian, deceased
  • ASSAYS FOR NEUTRALIZING ANTIBODIES
    Publication number: 20070099245
    Abstract: This invention relates to assays for the detection of neutralizing antibodies. Further, this invention relates to assays for the detection of neutralizing antibodies specific for bone morphogenetic protein 2 (BMP-2) or capable of inhibiting at least one of the biological activities of BMP-2.
    Type: Application
    Filed: September 29, 2006
    Publication date: May 3, 2007
    Inventors: Boris Gorovits, John Nowak, Denise O'Hara, William Dickerson, Tony Celeste
  • Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
    Publication number: 20060251645
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: December 5, 2005
    Publication date: November 9, 2006
    Inventors: Man Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Celniker, Mary Collins, Samuel Goldman, Gary Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida Veldman
  • Detection of an immune response to GDF-8 modulating agents
    Publication number: 20060240488
    Abstract: This disclosure provides methods for the detection of antibodies to a GDF-8 modulating agent such as, e.g., MYO-029, in a biological sample. Methods to detect an immune response to a GDF-8 modulating agent are also included. In particular, methods to assess an immune response in animals, including humans, to a GDF-8 modulating agent such as a GDF-8 inhibitor are provided herein.
    Type: Application
    Filed: March 23, 2006
    Publication date: October 26, 2006
    Inventors: John Nowak, Denise O'Hara, John Cryan, Teresa Caiazzo, Alison Joyce, Joseph Rajewski, Shujun Sun, Neil Wolfman
  • Antibodies against CTLA4 and uses therefor
    Publication number: 20060165706
    Abstract: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.
    Type: Application
    Filed: December 29, 2005
    Publication date: July 27, 2006
    Applicant: Genetics Institute, LLC
    Inventors: Beatriz Carreno, Clive Wood, Katherine Turner, Mary Collins, Gary Gray, Donna Morris, Denise O'Hara, Paul Hinton, Naoya Tsurushita
  • Antibodies against CTLA4
    Patent number: 7034121
    Abstract: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: April 25, 2006
    Assignee: Genetics Institue, LLC
    Inventors: Beatriz M. Carreno, Clive Wood, Katherine Turner, Mary Collins, Gary S. Gray, Donna Morris, Denise O'Hara, Paul R. Hinton, Naoya Tsurushita
  • Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins
    Patent number: 6984383
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: January 10, 2006
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
    Patent number: 6972125
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 6, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
    Publication number: 20050208042
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: November 12, 2004
    Publication date: September 22, 2005
    Inventors: Man Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Celniker, Mary Collins, Samuel Goldman, Gary Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida Veldman
  • Humanized immunoglobulin reactive with B7 therewith
    Patent number: 6913747
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: July 5, 2005
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith
    Patent number: 6827934
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: December 7, 2004
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman, Gary S. Gray